A substantial proportion of respondents believed that preimplantation genetic testing should be discussed with patients who harbor pathogenic BRCA mutation variants (n = 42, 75%), those who are diagnosed with Lynch syndrome in whom endometrial aberrations have not yet occurred (n = 38, 67.8%), and those who are known to have genetic variants in homologous recombination genes other than BRCA1 or BRCA2 (e.g., RAD51C, RAD51D, BRIP1, etc.)(n = 36, 64.3%). This evidence concerns the gene BRCA1 and Lynch syndrome.